Norgine Ventures

AI Verified

Location

United Kingdom

Investor type

Venture Capital

Current investment status

00 00 00

Website

http://www.norgineventures.com/

Linkedin

00 00 00

Company address

Widewater Place, South Harefield, London Borough of Hillingdon, Greater London, England, UB9 6NS, United Kingdom

Founding year

2012

Twitter

00 00 00

Facebook

00 00 00

Criteria Requirements Match
Regions
00 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 00
00
Countries
00 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 00
00
Sector
00 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 00
00
Impact Area
00 00 00
Stage
00 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 00
00
Ticket size
00 00 00
-
00 00 00
USD
00
Monetization model
00 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 00
00
Product readiness
00 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 00
00
Client types
00 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 00
00
Min. revenue
00 00 00
USD
00
Other
00 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 00
-

Unlock Free Premium Insights

Discover how well you match with this investor and reach out on the Raise Better platform.

  • Advanced matching algorithm
  • Detailed compatibility scores
  • Priority investor access
Create Free Account
Company Description
Norgine is a uniquely positioned, specialty pharmaceutical and consumer healthcare company, with more than €500 million of annual revenues and a 120-year track record of bringing life-changing products to patients and consumers across their core markets of Western Europe, Australia, and New Zealand. Today's Norgine is a nimble, innovative, and high-performing company that has been transformed by a relentless focus on operational excellence to do the right thing by patients, push boundaries, and take strides into new therapeutic areas. The company's integrated approach – strong commercial capabilities, deep medical, regulatory and clinical expertise, in-house manufacturing, robust supply networks, and best-in-class enabling functions – ensures delivery of high-quality, transformative medicines quickly and effectively to more than 25 million patients annually.
Highlights
A specialty pharmaceutical company with €500M+ annual revenue
Serving 25M+ patients with transformative medicines annually

Ready to raise better?

Create your Free Account!